A reduced frequency of each of the three KIR/ligand combinations was observed in AML and NHL patients, but neither association remained significant after correction, suggesting there is likely limited improvement in protection when considering ligand over that offered by KIR alone. Here, KIR3DL1 is linked to non-Hodgkin lymphoma.